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ABSTRACT 
katG is ·the sble gene encoding for catalase peroxidase enzyme in 
Mycohactertom tuuerculosis enabling its swvival in the host macrophage. This same 
gene has been indicted to play an important role in forming the killing effect ·of 
isoniazid (.INH), a major drug used in the treatment of tuberculosis (TB). It has been 
indicated that the formation of new generation drugs for TB will be connected to 
further understanding this interaction and the study of the structures of the .katG 
gene. 
The high molecular weight genomic DNA. of MycobtH:Jerium.tuberculafiJ;.of 
the clinical strain MTB69/03 from HUSM has successfully been isolated through a 
modification of the method in D. van Soolingen et. al .. Two primers with extra .sites 
for the excision sites of hcoR 1 and Hindi// were successfully used to produce a 
DNA product of 2252 base pairs. The product was then inserted into a pCR®2.1-
TOPO® plasmid vector. The insert was confirmed· by the use of both ·peR and 
restriction enzymes. 
The successfully confirmed inserted plasmids were then sent for sequencing. 
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ABSTRAK 
katG mempakan gen tunggal bagi enzim katalase dan· peroksidase dalam 
Mycobacterium tuber~--ulosis dan berfimgsi dalam membolehkan urganisma· tersebut 
hidup dalam makrofaj perumah. Gen tersebut turut memainkan peranan penting 
dalarn kesam membunuh isoniazid (INH) yang merupakan drug penting dalam 
tnengubati kes-kes tuberculosis {TB). Kajian telah menunjukkan bahawa 
penghasilan drug TB yang baru akan bergantung pada pemahaman tentang stl'uktm 
katG dan interaksi katG dan INH. 
DNA genomik Mycobacterium hlherculosis yang mempunyai berat molekul 
tinggi telah diasingkan dari strain klinikal MTB69/03 yang diperolehi dari IIDSM 
Teknik yang digunakan adalah modifibsi.teknik yang .ditunjukkan dalam .D. van 
Soolingen et. a/ .. Dua primer yang mempunyai kawasan pemotongan untuk EcoRl 
and Hind/11 telah digunakan dan telab beJjaya menghasilkan produk DNA yang 
sebesar 2232 pasangan bes. 'Produk tersebut dimasukkan ke dalam vektor plasmid 
pG~®Z.l-TO.PO®. Konfonnasi kemasukkan. primer _yan.g betu1 dilakukan melaui 
PCR dan menggunakan enzim 
Plasmid yang telah dipastikan betul dimasukkan produk kemudiannya 




Tuberculosis is a disease that bas long plagued man for many centuries. The 
earliest known name of this disease is Phthisis ("to waste") by the Greeks. It has also 
been known as consumption in the 1800s, wasting disease, and the white plague. 
This disease is known as the leading cause of death from a single infectious agent, 
with ·a prevalence of greater than 1.6 billion people (Whitney and Wainberg, 2002). 
Until the mid-1800s, people thought that tuberculosis, or TB, was bereditaJy~ ln 
1865 a .french surgeon, Jean-Antoine Villemin, proved that TB was contagiou~ and 
. in.lS82 .a German-scientist named Robert. Koch .discov.ered.thebacterimn .. that etuses 
TB, Mycobacterium tuherculo!;;is. 
TB is caused by an organism called Mycobacterium tuberculosis (MTB) also 
sometimes called as the tubercle baciJii. ·It is a member of the genus mycobacteriwn 
which consists of members of the MiB. complex and more than 80 $J1eeies of non-
tubercular mycobacteria inciuding pathogenic, opportunistic and non pathogenic 
species (Soini et al., 2001 ). Mycobacteria can cause a variety of diseases. Sotne 
mycobacteria are called tuberculous mycobacteria because they cause TB or 
diseases similar to TB. These mycobacteria are MTB, M bovis, and M. africanunl. 
Other mycobacteria are called non-tuberculous mycobacteria because they do not 
cause TB. One common type of nontuberculous mycobacteria is M avium complex. 
Non-tuberculous mycobacteria are not usually spread from person to person. 
Tuberculosis (TB) is a commooicable chronic granulomatous disease caused 
by MrB. It usually involves the lungs but may effect any other organ or tissue in the 
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body (Kumar, et a/.,2003). Tuberculosis is normally spread through airborne 
traitsmission of droplet nuclei containing the MTB bacili A majority of cases 
involves the lungs and is known as pulmonary tuberculosis wbere as extra 
pulmonary tuberculosis is due to the infection of other parts of the human body. 
About 80-90% of tuberculosis involves pulmonary tuberculosis and 10-20% 
involves extra pulmonmy tuberculosis. 
1.2 Epidemiology. 
There is archaeological evidence that tuberculosis has been occurring in 
human population for over 3000 years. This disease has been documented in 
analyses of mwnmies and skeletons which show deformities and lesions simi1ar to 
that of a TB patient. Among the places that this evidence bas been found include 
North Africa, Europe and even the Americas. There is no evidence of tuberculosis in 
sub-Sahamn Africa, East Asia, or the Pacific until after con1act was initiated with the 
Europeans, during the period of colonization (Aeras, 2005). 
Tuberculosis grew to epidemic proportions in Europe beginning in the early 
1600's as populations shifted to expanding cities and population densities increased 
The worsening of the environmental factors due to pollution, the degradation -of 
sanitation due to the mass translocation as weJI as the huge collection of individuals 
there lead to the spread ofTB. Tuberculosis came to be the leading calL~ of death in 
Western Europe in the 18th and early 19tb centuries (Whitney and Wainberg, 2002). 
In the 19th century there was a decline in tuberculosis that was accelerated by 
the development of effective chemotherapy for tuberculosis iJJD the second half of the 
20th Century ( Aeras,2005). One explanation of this decline is the rise in economic 
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conditions and the improvements in sanitation. Another reason might have been the 
segregation of individuals infected with TB from the general public via the use of 
sanatoriums. In the Jess industria1ized parts of the world, the increase in tuberculosis 
occurred much later but was later halted by improving conditions in health and 
standards of living as well as the development and use dispersion of TB vaccines_ 
Unfortunately, this trend has been shown to be reversed. The World Health 
Organintion (WHO) bas reported that there are more than 8 million new cases of 
active disease each year and that 3 million people die annually from tuberculosis. 
The prevalence of TB is estimated to be over 1.6 billion_ people and is the cause of 
7% of all death in developing countries (Rouse e1 al., 1995). People in high risk 
groups in acquiring this disease are patients coinfected with HIV, prison inmates, 
and professionals who work with people in these high risk groups (O~Brien e1 al., 
1995). 
A model by Dye· C. in his publication Epidemiology, in Clinical 
Tuberculosis, 3nt Edition show that tuberculosis is on tbe increase and that the 
nwnber of cases grew 1. 7% per year from 1997 to 2000 and that with the preSent 
trends there will be 9-10 million new cases in 2010 (Aeras, 2005). The rise in TB 
infection could be attributed to four main factors. Firstly is tbe impact of lllV I AIDS 
in those countries were the epidemics co-exist. HIV infection rates among TB cases 
exceed 60% in South Africa, Zimbabwe and Zambia. Second, 1he impact of 
declining public health infrastructure in the world may via the worsening urban 
social and economic conditions result in the TB has resurged in the past decade 
(Rouse et a/., 1994 ). Third, ·the mixing of prison with civiliam populations and lastly, 
recent improved surveillance and case reporting as other possible causes may be 
detecting the true prevalence of the disease. 
Another further disturbing trend in the outbreak is 1be emergence of multi-
drug resistant strains of the Mycobacterium, MDR-MTB. An important reason for 
this trend is patient non-comp1iance and de1ays in obtaining susceptibility data 
which still continue to be a hindrance to the elimination and instead fiuther 
exacerbate the development of MDR-MTB (Peloquin, 1993). lviDR TB has also 
been recognized as the cause of mortaJity for 70-900;{, of AIDS patients who develop 
TB (CDC, 2005) and the trend seems to be growing. WHO surveys report drug 
resistance in MTB isolates at rates of 1. 7-36.9% in alJ 58 countries surveyed 
between 1996 and 1999. Mutants resistant to isoniazid (INH) is recognized as the 
most prevalent accounting for as much as 26% clinical MDR-MTB isolates in the 
USA (Banerjee, 1994). 
1.3 Pathogenesis 
Tuberculosis (TB) is a communicable chronic granulomatous disease caused 
by Mycobacterium tubercu/o.r;i.Y (MTB) (Kumar et al., 2003) .. It is spread via droplet 
nuclei in the air are about 1 to 5 microns in diameter (CDC, 2005) and can remain 
suspended in the air for several hours, depending on the environment. When a 
person inhales air containing particles expelled by an infectious person, most of the 
larger particles become lodged in the upper respiratory tract, where infection is 
unlikely to develop. However, the droplet nuclei may reach the alveoli, where 
infection begins. (Figure 2). 
In, primary TB, an unsensitized individual or an mdividual never before 
exposed to the mycobacteria is infected by MTB. When Mm is inhaled and enters 
the lungs via alveoli, the bacterium becomes aggressively attacked and engulfed by 
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macrophages. But where other bacteria succumb to the attack, TB survives the 
macrophage with the aid of the "oxidative burst" mechanism which is due to the 
effects of superoxide dismutase and catalase-peroxidase which are enzymes that 
scavenge the oxygen radicals used as killing mechanisms by the macrophages. The 
TB will then be taken up by the alveolar macrophage and multiply in tbem. Once the 
mycobacteria gains entry into the macrophage, it inhibits normal bacteriacidal 
effects by manipulation of endosomal pH and arresting endosomal matmation 
(Kwnar et al., 2003 ). 
A small amount of the TB bacilli will spread through the regional lymph 
nodes and then through the bloodstream to more distant tissues and mgans including 
areas such as kidneys, brains and bone4 Within 2 to 10 weeks after infection, the 
immmte system usually intervenes. The immune response of hypersensitivity and 
resistance to the organism halts the multiplication of the tubercle bacilli and prevents 
fiuther spread In these instances, inflammatory conditions consolidate around the 
area of the MTB infection known as the Ghon focus which is also followed by tissue 
necrosis and scarring. This series of scarred tissue and consolidated cells are known 
as Gohn's complex. During this time, the patient usually doestft suffer any 
symptoms other than a slight fever due to the infection. m this instance, tbe TB 
infection may resolve itself but usually, the complex may harbour viable MTB 
which may survive for years before being reactivated in secondary lesions. 
In certain cases the disease may progress as progressive pnmary 
tuberculosis. This occurs when the MTB overcomes the defenses of the inmnme 
system and begin to multiply. This occurs in immunocompromised individuals or as 
the result of impainnent in the defence mechanisms. The risk may be approximately 
3 times greater with diabetes to more than 100 times greater for HIV infected 
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persons compared to those who do not have the disease (COC, 2005). Other forms 
of this state are due to substance abuse=' renal disease, neoplasia and hematological 
disorders. 
Another scenario is when secondary TB infection or reactivation TB occurs. 
This is due to the reactivation of donnant primary lesion due to weakness of host 
resistance as well as exogenous reinfection of the host. In approximately 5% of 
persons who have been i'nfected with MTB, TB disease will develop in the first or 
second year after infection. In another 5%, disease will develop later in their lives. 
The remaining 90% will stay infected, but free of disease, for the rest of their lives 
(CDC, 2005). This can occur within the lung or in other dislant organs because of 
dissemination and seeding of the MTB into smroWlding tissue via blood and the 
lymphatics. About 80-90% of TB involves pulmonary TB and 10-20% involves 
extra pulmonary TB (Kwnar et al., 2003). In extra pulmonary TB, the infection 
occurs in lungs, larynx, lymph nodes, brain, kidneys, bones or joints. 
As the infection progresses, the infection causes Jocalized damage to the 
tissue and then systemic damage. The majority of the infection which begins with 
pulmonary TB will cause progressive erosion into the bronchus of the lung forming 
cavities in the lung and the fonnation of fibrous tissue. Via the cavity the MTB can 
be disseminated into the air via the airways as well as via sputum. Higb amounts of 
sputum, mucoid in the beginning and later purulent wiU appear followed by 
hemoptysis. 
Through the airways and through the lymphatic and vascular channels~ the 
progressively multiplying MTB, may then cause military TB in which the MTB can 
then drain out into the blood stream and go to the heart where it is distributed to the 
arteries all over the body. Almost every organ of the body can them 1be seeded by 
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To date only 9 drugs have been approved by the FDA for tbe treatment of 
tuberculosis infections. Very few experimental drugs are available (Peloquin, 1993) 
and most of these drugs have been extensively used for the treatment of the disease. 
Due to the highly contagious and very stubborn nature of the disease, the treafment 
usually includes combinations of these drugs. The most prescribed form of treatment 
is that of the Arkansas regimen from the Unites States. It is a short comse treatment 
is 6-9 months long. and is only possible when isolates remain susceptible to both 
isoniazid and rifampin (Peloquin, 1993). The fiiSt line of drugs used in the fight 
against TB are isoniazid, rifampin, pyramidazole and ethambutol. The second line 
drugs or drugs used to complement these drugs include capreomy~ cycloserine, 
ethionamide, kanamycin, and the fluoroquinoles. 
Initially, TB was in a decline especially in the developing COWltries~ This 
was due mainly to the use of mass vaccination as well as improving public 
healthcare, treatment and the decline of poverty .. Unfortunately, the trend shifted 
especially seen in the United States in the early 80s. This was mainly due to 
coinfection with the HIV virus (Haeym et al., 1994). Another major :reason for this 
rise was the appearance of multidrug resistant strains of MIB, lviDR-MTB. These 
strains showed great resilience against the drugs used for the treatment against TB, 
having mortality rates significantly higher than that of drug sensitive strains (O"brien 
et al., 1996). 
In line with these trends, the WHO has been actively pmsuing steps in 
eradicating this menace. It introduced DOTS (directly observed therapy, short 
course) and the Stop-TB Partnership, which encompassed proper baDJdling of the 
disease, management and overall reporting of the disease through passive case-
finding and treatment of the cases. It was based on the believe that proper 
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MTB foci. It is most prominent however in the liver~ bone, spleen, adrenal, 
meninges, kidneys, fallopian tubes and epidedymis (Kumar et al. , 2003). 
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Figure 1: A chart depicting the pathogenesis of Mycobacterium To.berculosil (CDC, 2005) 
1.4 Control and Prevention 
Because of this of the slow growth rate of the causative agent, isolation and 
identification, and drug susceptibility testing of this organism can take severaJ weeks 
or longer (Soini et al., 2001). A complete medical evaluation for TB includes a 
medical history, a physical examination, a Mantoux tuberculin skin test, a chest 
radiograph, and any appropriate bacteriologic or histologic examinations. 
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prescription and implementation of proper chemotherapy combining isoniazid, 
rifampin, pyrazinamide and 'ethambutol could eventually prove to be the answer 
(Haeym eta/., 1994). Unfortunately, patient non-comp1iance~ rising poverty and rise 
in drug resistance continue to be the main problems in the treatment of the disease. 
A cure-rate of over 90% is possible with this approach and Dye notes that the 
average trea1ment success rate was 82% in 155 national programs (Aeras, 2005). 
However, coverage is far from complete and at the current rates of DOTS expansion 
the target of70% case detection will not be reached until after 2010 (Aeres, 2005). 
1.5 katG gene 
katG is a gene with is 2223 bp in size which encodes the catalase peroxidase 
enzyme in M1B (Ng et al., 2004) and is imperative in conferring a selective 
advantage on the MTB by possibly enabling it to withstand hostile environments 
(Haeym eta/., 1995). This heme-containing enzyme is part of a group of proteins 
known as hydroperoxidase I (HPI) or catalase peroxisdase group (DeVIto & Morris, 
2002). The HPI protein is a bifunctional protein made out of catalase which turns 
hydrogen peroxide into water and oxygen (2H20r-~H20 + 0 2) Peroxidase on the 
other hand accepts protons to tum hydrogen peroxide into water (H20 2-+H20) 
(Haeym & Cole, 1997). 
The significance of katG was highlighted by Zhang et al., when it was foWld 
tbat the deletion of this gene conferred isoniazid resistance,INHR to M tuberculosis 
(O.,Brien eta/., 1995). Isoniazid (INH) was first reported to be effective against 
MTB in 1952 and has been playing a pivotal role in the fight against TB since then 
(Quemard eta/., 1995). This drug is actually a prodrug, and has beeJD shown to be 
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very effective against MTB with an MIC as low as 0.02JJ.g/p.l (Haeym eta/., 1992). 
The function is essential in the use of present treatments ae;»inst TB. Although used 
extensively, the exact mechanism of action of this drug has still eluded us. Studies 
by J.A. Ainsa eta/. (2001), and Wimpenny, (1967) that the enzyme produced by the 
katG gene activates the lNH and is reacted once again before it becomes a form 
toxic to MTB. This new toxic fonn wil1 then bind to the NADH and the complex 
then inactivates inhA, a gene that shares similar expression factors as katG. This is 
twn effects the action of the type 11 fatty acid synthase (F ASD) impairing 
biosynthesis of mycolic acid and distrupts the cell wall production of the MTB 
(Ainsa et a/.,2001). The katG protein has also been suggested to aid in the transport 
of INH into the cell (Rouse & Morris, 1995). Figure 3 contains an outline diagram 
of aU the many theories put forth on the mechanisms of katG and its association with 
lNH. 
lNH resistant strains of MTB make up 25% of most identified MTB strains. 
60-70% of INH resistant strains have been linked to defects in katG gene. (Whimey 
& Wainberg, 2002) Patients infected with this strain showing this kind of resistance 
show poor prognosis with 46% of patients who tmdergo trtmment having failw-es of 
relapses (Quennard eta/., 1995). Only about 500A. will eventually be able to have 
negative sputum shedding of the virus (Goble, 1993). 
1~ 
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Figure 2: The effects of katG and katG mutagens on Mycobacterium tBberculosis survival with 
treatment with Isoniazid (lNH). 
1.6 Review of Literature 
Zhang et a/. (1992) demonstrated that INH resistance in some isolates was 
conferred by a total gene deletion of the katG gene which encodes catalase-
peroxidase activity (O'Brien, 1995). This has led to the further understanding of the 
functions of isoniazid (INH) that had up till then been a mystery. 
Haeym eta/. (1993) in the characterization study ofkatG, concluded that the 
enzyme produced by katG interacts with INH and converts it into a toxic derivative 
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which is acted upon by a second unknown mechanism. This study was expanded by 
Ainsa eta/. (2001), and Wimpenny, (1967) that each concluded that the enzyme 
produced by the katG gene activates the INH and undergoes another reaction before 
it becomes a toxic form to MTB. With this a basic theory on the wuddngs on the 
lNH action was founded. 
Pym et al., (2001) in their study of the regulation and virulence of kat(i and 
its promoters concluded that antimycobacterial activity of 1NH is limited by the rate 
of activation and not interaction with other cellular processes. Thus, INH analogues 
was the rational strategy for a new generation INH-based drugs. 
De Vito & Morris (2002) in studying the structures of the kat.G gene found 
that a rational design of INH-based analogues is difficult because katG protein 
crystal structure and tertiary and quartenary structural determinants still remained 
unknown. 
Recently the genome of the MTB laboratory strain ID7R V was completely 
sequenced (GenBank accession no. NC 000962) and allows for better research and 
understanding of the relationship of the genes. 
Due to these findings, it can be concluded that the structure of katG is an 
important detenninant in finding an alternative cme for TB in the near future. The 
isolation and expression of the katG gene is possible and bas been performed~ The 
molecular structures and structural determinants can now be studied to further 
expand on the present knowledge on the interactions of katG with isoniazid and the 
killing effects. This would allow better understanding on ways to deal with the TB 
epidemic and enable the rational design of INH-based demratives/analogues which 
will be more effective than INH. 
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1. 7 Objectives 
A1though the katG gene has been cloned and the sequence is known, the 
structure of this enzyme, however, has yet to be elucidated The objective of this 
study is to clone the katG gene which will later be used to express the enzyme for 
study of the protein structure by X-ray crystallisation. 
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1.7 Flowchart of Project 
PCR of katG gene from genomic .Mycobacterium tuherculosi.." 
DNA 
+ 
A-Tailing ofPCR Product 
t 
Cloning into plasmid vector pCR®2.1-TOPO® 
t 
Tranasformation into competent cel1s (TOP 1 0) 
Selection of positive clones 
Characterization of 
Recombinant plasmid by 
PCR 
Characterization of 
recombinant plasmid by 
RestrictionE~eandygs 
Gene of interest (katG 1 gene) 
2252kb 
Final Characterization by 
Sequencing 




2.1 Reagents and Chemicals 
No Reagents and Chemicals Supplier 
1 7H9 Middle Brooke Pifco Lab, USA 
2 OADC enrichment media Becton Dickinson & Co., 
USA 
3 Sodium pyruvate lOOmM/L Bio-Rad, USA 
4 Tris base Amres Co. ®~USA 
5 EDTA Promega, USA 
6 Lysozymes Merek, Germany 
7 Sodium dodecyl sulphate Bio-Rad, USA 
8 Protinasek Invitrogen, USA 
9 Sodium chloride (NaCl) Merck, Gemany 
10 N-acetyl-N.,N,N-trimethylammonium Sigma, USA 
bromide 
(CTAB) 
11 Isoamyl-alcohol BDHAnalar 
ll Chloroform M&.B Laboratory 
13 Isopropanol Merek, Germany 
14 70% ethanol Merck, Gennany 
15 Sodium Hydroxide (NaOH) Merck, Gennany 
16 Glacial acetic acid Bio-Rad, USA 
17 Agarose Promega, USA 
18 OmngeG Sigma, USA 
20 
19 Ethidium bromide Sigma, USA 
20 Sucrose AnalaR®, Germany 
21 Tryptone Pronidasa, Madrid 
22 Yeast extract Pronidasa, Madrid 
23 E. coli (TOPlO), -70°C Invitrogen, USA 
24 Magnesium chloride (MgCh) AnalaR®, Germany 
25 Calcium chloride (CaCh) AnalaR®, Germany 
26 Glycerol 10% Sigma, USA 
27 Kanamycin Promega, USA 
28 X-Gal Promega, USA 
29 Lambda DNA/ Hind III marker Promega, USA 
30 1 OObp DNA ladder Promega, USA 
31 Blue/Orange 6x Loading Dye Promega, USA 
2.2 Kits 
No. Kits Supplier 
l Taq DNA Polymerase: Fennentas, USA 
Taq DNA Polymerase 
1 Ox Reaction Buffer 
MgC12 
dNTPmix 
2 Pfu DNA Polymerase: Fennentas, USA 
Pfu DNA Polymerase 




3 Taq DNA Polymerase: Promega, USA 
Taq DNA Polymerase 
1 Ox Reaction Buffer 
MgCh 
dNTPmix 
4 QIA Quick® Gel Extraction kit QIAGEN,USA 
s TOPO® Cloning Reaction Invitrogen, USA 
pCR®2.1-TOPO® vector 
salt solution 
6 QIAprep® Miniprep QIAGEN, USA 
7 EcoRI Restirction Enzyme Fennentas, USA 
EcoR/ restriction enzyme 
lOx buffer 
2.3 Equipment 
No. Equipment Supplier 
1 Dragon 3002 Analytical Balance Mettler Toledo, Canada 
2 Cyberscan l 000 pH meter Eutech, UK 
J TBVX Hexomix Water Bath Heto-Higb Technology, 
Scandinavia 
4 Innova 4080 Rotary Shaker New Brunswick 
Scientific Co. Inc. USA 
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5 Pipettes Eppendorf, Germany 
6 EppendorfFixed Angle Rotar Microcentrifuge Eppendorf AG, 
Germany 
7 Refrigerated Centrifuge 581 OR Eppendorf, Gennany 
8 Gene AMP PCR System 9700 Thennal cycler Applied 
Biosyst~USA 
9 PTC-200 DNA Engine (Peltier Thetmal MJ Researeh, USA 
Cycler) 
10 Super Showerwave Microwave Oven Sanyo, 
11 Agarose Gel Electrophoresis Apparatus CBS Scientific Co.~USA 
12 Elite300Plus Wealtec, USA 
13 UVP Bioimaging UVP Image Analyzer Lab Companion, USA 
14 UV-25 UV Transilluminator Hoefer, UK 
15 Nanodrop ™ ND-100 Spectrophotometer Nnanodropnt,USA 
16 Shaking Incubator SI600 Lab Companion, USA 
17 Microbiological Incubator Binder, Gennany 
18 Lambda EZ 150 UV-Vis Spectrophotomer Perkin Elmer, USA 
23 
3.0 PREPARATION OF REAGENTS 
3.1 Preparation of 7H9 Middle Brooke broth 
7H9 Middle Brooke broth was prepared by dissolving 2.35g of the powdered 
broth in 450mL deionised distilled water. 19.09mL sodiwn pyruvate 100 mMIL 
which bas been filtered prior to use is then pipetted. The solution is then mixed 
thoroughly and aliquoted into flasks. 50 mL OADC enrichment media is then added 
to the solution prior to use. 
3.2 Preparation of 10xTE buffer 
lOx TE buffer was prepared from the adding 12.1g of Tris in pH8.0 with 
3.7g lmM EDTA. The pH was adjusted with sodimn hydroxide. Deionised distiJied 
water was then added to make up the solution to a level of 100 mL. The solution was 
autoclaved at 121 "C for 15 minutes and stored at room tempemture. 
3.3 Preparation of 10mglmL lysozymes 
The lysozymes are prepared into concentrations of 1 OmglmL by adding 0.1 g 
of the powdered lysozymes provided with 10 mL de ionised distilled water.. The 
soJution is then thoroughly mixed and filter sterilised prior to use. 
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